Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hagner PR"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stokes ME; Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, NJ, USA., Wenzl K; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Huang CC; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Ortiz M; Informatics and Predictive Sciences, Bristol Myers Squibb, Seville, Spain., Hsu CC; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Maurer MJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Stong N; Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, NJ, USA., Nakayama Y; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Wu L; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Chiu H; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Polonskaia A; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Danziger SA; BMS at the time the study was conducted, Amazon, Seattle, WA, USA., Towfic F; BMS at the time the study was conducted, Prometheus Biosciences, San Diego, CA, USA., Parker J; LifeEDIT Therapeutics, Research Triangle Park, Durham, NC, USA., King RL; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Link BK; Division of Hematology, Oncology, Blood and Marrow Transplant, University of Iowa, Iowa City, IA, USA., Slager SL; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Sarangi V; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Asmann YW; Department of Health Science Research, Mayo Clinic, Jacksonville, FL, USA., Novak JP; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sudhindra A; Clinical Research and Development, Bristol Myers Squibb, Summit, NJ, USA., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hagner PR; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Cerhan JR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Novak AJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gandhi AK; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA. anita.gandhi@bms.com.
Publikováno v:
Nature communications [Nat Commun] 2024 Aug 08; Vol. 15 (1), pp. 6790. Date of Electronic Publication: 2024 Aug 08.
Autor:
Jeyaraju DV; Bristol Myers Squibb, Summit, NJ., Alapa M; Bristol Myers Squibb, Summit, NJ., Polonskaia A; Bristol Myers Squibb, Summit, NJ., Risueño A; CITRE, Bristol Myers Squibb, Seville., Subramanyam P; BBRC, Bangalore., Anand A; BBRC, Bangalore., Ghosh K; Bristol Myers Squibb, Bangalore., Kyriakopoulos C; CITRE, Bristol Myers Squibb, Seville., Hemerich D; Bristol Myers Squibb, Summit, NJ., Hurren R; Princess Margaret Cancer Centre, Toronto, ON., Wang X; Princess Margaret Cancer Centre, Toronto, ON., Gronda M; Princess Margaret Cancer Centre, Toronto, ON., Ahsan A; Bristol Myers Squibb, Summit, NJ., Chiu H; Bristol Myers Squibb, Summit, NJ., Thomas G; Princess Margaret Cancer Centre, Toronto, ON., Lind EF; Department of Molecular Microbiology and the Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Menezes DL; Bristol Myers Squibb, San Francisco, CA., Schimmer AD; Princess Margaret Cancer Centre, Toronto, ON., Hagner PR; Bristol Myers Squibb, Summit, NJ., Gandhi A; Bristol Myers Squibb, Summit, NJ., Thakurta AG; Bristol Myers Squibb, Summit, NJ. anjan.thakurta@ndorms.ox.ac.uk.
Publikováno v:
Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1082-1094. Date of Electronic Publication: 2024 Apr 01.
Autor:
Apollonio B; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Spada F; BRC Advanced Cytometry Platform and., Petrov N; BRC Advanced Cytometry Platform and., Cozzetto D; BRC Translational Bioinformatics at Guy's and St. Thomas's NHS Foundation Trust and King's College London, London, United Kingdom.; Division of Digestive Diseases, Faculty of Medicine, Imperial College London, London, United Kingdom., Papazoglou D; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Jarvis P; 5th Surgical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece., Kannambath S; BRC Genomics Research Platform at Guy's and St. Thomas's NHS Foundation Trust and King's College London, London, United Kingdom., Terranova-Barberio M; BRC Advanced Cytometry Platform and., Amini RM; Department of Immunology, Genetics and Pathology, Uppsala University and Hospital, Uppsala, Sweden., Enblad G; Department of Immunology, Genetics and Pathology, Uppsala University and Hospital, Uppsala, Sweden., Graham C; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Benjamin R; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Phillips E; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Ellis R; BRC Advanced Cytometry Platform and., Nuamah R; BRC Genomics Research Platform at Guy's and St. Thomas's NHS Foundation Trust and King's College London, London, United Kingdom., Saqi M; BRC Translational Bioinformatics at Guy's and St. Thomas's NHS Foundation Trust and King's College London, London, United Kingdom., Calado DP; Immunity & Cancer Laboratory, Francis Crick Institute, London, United Kingdom., Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Sutton LA; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Salisbury J; Department of Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom., Zacharioudakis G; 5th Surgical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece., Vardi A; Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece., Hagner PR; Bristol-Myers Squibb, Summit, New Jersey, USA., Gandhi AK; Bristol-Myers Squibb, Summit, New Jersey, USA., Bacac M; Roche Innovation Center Zurich, Schlieren, Switzerland., Claus C; Roche Innovation Center Zurich, Schlieren, Switzerland., Umana P; Roche Innovation Center Zurich, Schlieren, Switzerland., Jarrett RF; MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom., Klein C; Roche Innovation Center Zurich, Schlieren, Switzerland., Deutsch A; Division of Hematology, Medical University of Graz, Graz, Austria., Ramsay AG; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2023 Jul 03; Vol. 133 (13). Date of Electronic Publication: 2023 Jul 03.
Autor:
Hagner PR; Bristol Myers Squibb, Summit, New Jersey., Chiu H; Bristol Myers Squibb, Summit, New Jersey., Chopra VS; Genentech, San Francisco, California., Colombo M; Celgene Corporation, a Bristol Myers Squibb Company, Seville, Spain., Patel N; Loxo Oncology, San Francisco, California., Estevez MO; Celgene Corporation, a Bristol Myers Squibb Company, Seville, Spain., Waldman MF; Bristol Myers Squibb, Summit, New Jersey., Loos R; Celgene Corporation, a Bristol Myers Squibb Company, Seville, Spain., Towfic F; Bristol Myers Squibb, Summit, New Jersey., Gandhi AK; Bristol Myers Squibb, Summit, New Jersey.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3367-3377.
Autor:
Wu W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Nelson GM; Department of Biomedical Informatics, Harvard Medical School, Boston, MA., Koch R; Department of Hematology and Medical Oncology, University Medical Center Göttingen, Gottingen, Germany., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Heavican-Foral TB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Nirmal AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Liu H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Yang L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Duffy J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Powers F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Stevenson KE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jones MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Ng SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Wu G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jain S; Massachusetts General Hospital, Boston, MA., Xu R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Amaka S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Trevisani C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Donaldson NL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Hagner PR; Bristol Myers Squibb, Summit, NJ., de Leval L; The Lausanne University Hospital, CHUV, Lausanne, Switzerland., Gaulard P; Département de Pathologie, Université Paris-Est, Hôpital Henri-Mondor, INSERM U955, Créteil, France., Iqbal J; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE; and., Thakurta A; Bristol Myers Squibb, Summit, NJ., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Adelman K; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of MIT and Harvard University, Cambridge, MA.
Publikováno v:
Blood [Blood] 2022 Mar 31; Vol. 139 (13), pp. 2024-2037.
Autor:
Ribrag V; Institut Gustave Roussy Villejuif France., Chavez JC; H. Lee Moffitt Cancer Center & Research Institute Tampa Florida USA., Boccomini C; Candiolo Cancer Institute FPO-IRCCS Turin Italy., Kaplan J; Feinberg School of Medicine Northwestern University Chicago Illinois USA., Chandler JC; West Cancer Center Memphis Tennessee USA., Santoro A; Humanitas Clinical and Research Center IRCCS Humanitas University Rozzano-Milano Italy., Corradini P; IRCCS Istituto Nazionale dei Tumori University of Milano Milano Italy., Flinn IW; Sarah Cannon Research Institute Nashville Tennessee USA., Advani R; Stanford Cancer Institute Stanford California USA., Cassier PA; Centre Leon Berard Lyon France., Sangha R; Cross Cancer Institute Edmonton Canada., Kenkre VP; Division of Hematology/Oncology University of Wisconsin Madison Wisconsin USA., Isufi I; Yale Cancer Center New Haven Connecticut USA., Uttamsingh S; Bristol Myers Squibb Princeton New Jersey USA., Hagner PR; Bristol Myers Squibb Princeton New Jersey USA., Gandhi AK; Bristol Myers Squibb Princeton New Jersey USA., Shen F; Bristol Myers Squibb Princeton New Jersey USA., Michelliza S; Bristol Myers Squibb Princeton New Jersey USA., Haeske H; Bristol Myers Squibb Princeton New Jersey USA., Hege K; Bristol Myers Squibb Princeton New Jersey USA., Pourdehnad M; Bristol Myers Squibb Princeton New Jersey USA., Kuruvilla J; Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Canada.
Publikováno v:
EJHaem [EJHaem] 2022 Jan 14; Vol. 3 (1), pp. 139-153. Date of Electronic Publication: 2022 Jan 14 (Print Publication: 2022).
Autor:
Ioannou N; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Hagner PR; Bristol-Myers Squibb, Summit, NJ., Stokes M; Bristol-Myers Squibb, Summit, NJ., Gandhi AK; Bristol-Myers Squibb, Summit, NJ., Apollonio B; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Fanous M; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Papazoglou D; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Sutton LA; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden., Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Clinical Genetics, Karolinska University Hospital Solna, Stockholm, Sweden., Amini RM; Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Uppsala, Sweden., Chiu H; Bristol-Myers Squibb, Summit, NJ., Lopez-Girona A; Bristol-Myers Squibb, San Diego, CA., Janardhanan P; Bristol-Myers Squibb, San Diego, CA., Awan FT; Division of Hematology, The Ohio State University Cancer Center, Columbus, OH., Jones J; Bristol-Myers Squibb, Summit, NJ., Kay NE; Division of Hematology, Mayo Clinic, Rochester, MN., Shanafelt TD; Stanford University, School of Medicine, Stanford, CA., Tallman MS; Memorial Sloan-Kettering Cancer Center, New York, NY., Stamatopoulos K; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece., Patten PEM; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.; Department of Haematology, King's College Hospital NHS Foundation Trust, London, United Kingdom; and., Vardi A; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.; Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece., Ramsay AG; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Publikováno v:
Blood [Blood] 2021 Jan 14; Vol. 137 (2), pp. 216-231.
Autor:
Hatake K; Lymphoma/Hematology Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan., Chou T; Department of Hematology Oncology, Niigata Cancer Center Hospital, Niigata, Japan., Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan., Terui Y; Department of Hematology Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Kato H; Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan., Hirose T; Department of Hematology Oncology, Niigata Cancer Center Hospital, Niigata, Japan., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Pourdehnad M; Bristol Myers Squibb, Princeton, NJ, USA., Ogaki Y; Celgene K.K., A Bristol Myers Squibb Company, Tokyo, Japan., Fujimoto H; Celgene K.K., A Bristol Myers Squibb Company, Tokyo, Japan., Hagner PR; Bristol Myers Squibb, Princeton, NJ, USA., Yamamoto K; Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Publikováno v:
Cancer science [Cancer Sci] 2021 Jan; Vol. 112 (1), pp. 331-338. Date of Electronic Publication: 2020 Nov 26.